Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, cetuximab, and irinotecan after SBRT in RAS wild-type colorectal cancer
NCT05799443Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in colorectal cancer (CRC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05799443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799443.